Skip to main content
. Author manuscript; available in PMC: 2018 Oct 18.
Published in final edited form as: Eur J Pharmacol. 2008 Feb 5;584(2-3):213–221. doi: 10.1016/j.ejphar.2008.01.036

Table 3.

Inhibition potency (percentage inhibition) of various inhibitors for the reduction of daunorubicin by AKR1B10 wild-type protein

Inhibitors Concentration (μM) Inhibition (%)
Zopolrestat 20 43
50 47
EBPC 100 54
250 57
Fenofibrate 20 35
Wy 14,643 250 37
500 50
Sorbinil 100 31
250 37
Ciprofibrate 250 33
500 39
Fenofibric acid 250 25
500 35